LU90484I2 - Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables - Google Patents

Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables

Info

Publication number
LU90484I2
LU90484I2 LU90484C LU90484C LU90484I2 LU 90484 I2 LU90484 I2 LU 90484I2 LU 90484 C LU90484 C LU 90484C LU 90484 C LU90484 C LU 90484C LU 90484 I2 LU90484 I2 LU 90484I2
Authority
LU
Luxembourg
Prior art keywords
novorapid
derivatives
pharmaceutically acceptable
acceptable salts
insulin aspart
Prior art date
Application number
LU90484C
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK395685A external-priority patent/DK395685D0/da
Priority claimed from DK467785A external-priority patent/DK467785D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of LU90484I2 publication Critical patent/LU90484I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU90484C 1985-08-30 1999-12-21 Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables LU90484I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK395685A DK395685D0 (da) 1985-08-30 1985-08-30 Peptider
DK467785A DK467785D0 (da) 1985-10-14 1985-10-14 Peptider

Publications (1)

Publication Number Publication Date
LU90484I2 true LU90484I2 (fr) 2000-02-21

Family

ID=26067291

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90484C LU90484I2 (fr) 1985-08-30 1999-12-21 Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables

Country Status (25)

Country Link
US (1) US5618913A (fr)
EP (1) EP0214826B1 (fr)
JP (1) JP2662390B2 (fr)
KR (1) KR940000756B1 (fr)
CN (1) CN1029977C (fr)
AR (1) AR241801A1 (fr)
AT (1) ATE113061T1 (fr)
AU (1) AU593274B2 (fr)
CA (1) CA1306212C (fr)
CS (1) CS275613B6 (fr)
DD (1) DD268976A5 (fr)
DE (2) DE3650101T2 (fr)
ES (1) ES2001624A6 (fr)
FI (1) FI102182B (fr)
GR (1) GR862233B (fr)
HU (1) HU206518B (fr)
IE (1) IE66138B1 (fr)
IL (1) IL79887A (fr)
LU (1) LU90484I2 (fr)
NL (1) NL990042I2 (fr)
NO (2) NO177009C (fr)
NZ (1) NZ217406A (fr)
PH (1) PH25772A (fr)
PT (1) PT83278B (fr)
YU (2) YU46023B (fr)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK437786D0 (da) * 1986-09-12 1986-09-12 Nordisk Gentofte Insulinprecursorer
AU612141B2 (en) * 1987-02-25 1991-07-04 Novo Nordisk A/S Novel insulin derivatives
US4992417A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US4992418A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
CA1340772C (fr) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression et secretion de proteines heterologues dans une levure au moyen de sequences leader tronquees du facteur alpha
WO1990001038A1 (fr) * 1988-07-20 1990-02-08 Nordisk Gentofte A/S Analogues d'insuline humaine et preparations les contenant
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
AU641631B2 (en) * 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
US5716927A (en) * 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
ATE120762T1 (de) * 1989-04-20 1995-04-15 Sinai School Medicine Hepatospezifische insulin-analoga.
US5208217A (en) * 1989-04-20 1993-05-04 Mount Sinai School Of Medicine Of The City University Of New York Hepatospecific insulin analogues
DK155690D0 (da) * 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK158390D0 (da) * 1990-07-02 1990-07-02 Novo Nordisk As Nye peptider
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DK33591D0 (fr) * 1991-02-27 1991-02-27 Novo Nordisk As
ZA924448B (en) * 1991-06-21 1993-12-17 Lilly Co Eli Insulin Analogs
CZ158895A3 (en) * 1992-12-18 1995-12-13 Lilly Co Eli Insulin analog, process of its preparation and pharmaceutical composition containing thereof
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
AU6995794A (en) * 1993-06-21 1995-01-17 Novo Nordisk A/S Aspb28 insulin crystals
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
AU3562195A (en) * 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
BR9709845B1 (pt) * 1996-06-20 2008-11-18 preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001521004A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 脂肪酸−アシル化インスリン類似体
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
AU741037B2 (en) * 1998-02-23 2001-11-22 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
AUPP609198A0 (en) * 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
US6746853B1 (en) * 1999-05-19 2004-06-08 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
US6689747B2 (en) 2000-03-24 2004-02-10 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
JP2003532691A (ja) * 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
AR025646A1 (es) * 2000-09-13 2002-12-04 Beta Lab Sa Cepa de levaduras metilotroficas recombinantes productoras de un precursor de insulina, construcciones de adn y metodo para obtener la cepa.
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003031432A1 (fr) 2001-10-12 2003-04-17 Novo Nordisk A/S Nouvelles piperidines substituees
RU2376379C2 (ru) 2001-11-19 2009-12-20 Ново Нордиск А/С Способ получения инсулиновых соединений
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2004089896A1 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Composes actifs de la 11?-hydroxysteroide deshydrogenase de type 1
RU2381103C2 (ru) 2003-06-27 2010-02-10 Ново Нордиск А/С Контейнер для жидких фармацевтических композиций с высокими влагозащитными свойствами
US20060183667A1 (en) * 2003-07-11 2006-08-17 Novo Nordisk A/S Stabilised insulin compositions
WO2005005477A2 (fr) * 2003-07-11 2005-01-20 Novo Nordisk A/S Compositions d'insuline stabilisee
AU2004261319B2 (en) * 2003-07-25 2010-12-23 Conjuchem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
DK2107069T3 (da) 2003-08-05 2013-04-15 Novo Nordisk As Nye insulinderivater
EP2264065B1 (fr) 2003-08-05 2017-03-08 Novo Nordisk A/S Nouveaux derives de l'insuline
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
JP4800959B2 (ja) * 2003-11-13 2011-10-26 ノヴォ ノルディスク アー／エス 糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
PL1687019T3 (pl) 2003-11-20 2018-05-30 Novo Nordisk A/S Formulacje peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniach do wstrzykiwań
CN1902226A (zh) 2003-12-03 2007-01-24 诺和诺德公司 单链胰岛素
CN1898087A (zh) 2003-12-22 2007-01-17 诺沃挪第克公司 用于储存药物液体的透明、柔性、不可渗透的塑料容器
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
RU2393168C2 (ru) 2004-07-19 2010-06-27 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
CN102140875B (zh) 2004-11-04 2014-11-26 亨特道格拉斯有限公司 用于建筑开口的单轨道层叠板体遮蔽件
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
ES2428510T3 (es) 2005-02-02 2013-11-08 Novo Nordisk A/S Derivados de insulina
ES2435522T3 (es) 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
KR101286569B1 (ko) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 신규 약제
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
CN101243190B (zh) 2005-08-16 2015-05-13 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
BRPI0616054B8 (pt) 2005-09-14 2021-05-25 Sanofi Aventis Deutschland processo para a preparação de insulina, um análogo de insulina ou um derivado de insulina, tripsina porcina, método para sua produção, dna e vetor
PT1951658E (pt) 2005-11-17 2012-11-12 Lilly Co Eli Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas
EP2505593A1 (fr) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions renfermant de l'insuline acylée et du zinc et procédé de fabrication des dites compositions
US8343914B2 (en) * 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
WO2007096332A1 (fr) * 2006-02-21 2007-08-30 Novo Nordisk A/S Analogues d'insuline à chaîne unique et formules pharmaceutiques contenant lesdits analogues
ES2387955T3 (es) 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
DK2049475T3 (da) 2006-04-24 2012-03-05 Lilly Co Eli Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
JP5269766B2 (ja) 2006-05-09 2013-08-21 ノボ・ノルデイスク・エー／エス インスリン誘導体
BRPI0711370A2 (pt) 2006-05-29 2011-11-01 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)pi ridazina e seus sais e solvatos e seu uso como antagonista receptor h3 de histamina
WO2007140619A1 (fr) * 2006-06-08 2007-12-13 Diabecore Medical Inc. Oligomères d'insuline dérivés
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
US20090306337A1 (en) 2006-07-31 2009-12-10 Novo Nordisk A/S Pegylated, Extended Insulins
AU2007298919C1 (en) * 2006-09-22 2014-02-06 Novo Nordisk A/S Protease resistant insulin analogues
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2008049711A1 (fr) * 2006-10-27 2008-05-02 Novo Nordisk A/S Insuline à peptide ajouté
US10100098B2 (en) 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
US20120214963A1 (en) * 2011-02-23 2012-08-23 Elona Biotechnologies Aspart proinsulin compositions and methods of producing aspart insulin analogs therefrom
WO2008132224A2 (fr) 2007-04-30 2008-11-06 Novo Nordisk A/S Procédé de déshydratation d'une composition de protéine, composition de protéine déshydratée et composition pharmaceutique contenant la protéine déshydratée
WO2008139496A1 (fr) * 2007-05-16 2008-11-20 Bigtec Private Limited Insuline humaine de recombinaison et méthode associée
EP2164459A1 (fr) 2007-06-01 2010-03-24 Novo Nordisk A/S Compositions pharmaceutiques non aqueuses stables
EP2514406A1 (fr) 2007-06-01 2012-10-24 Novo Nordisk A/S Préconcentrés spontanément dispersibles comprenant un médicament peptidique dans un support solide ou semi-solide
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
JP5710253B2 (ja) 2007-08-13 2015-04-30 ノボ・ノルデイスク・エー／エス 速効型インスリンアナログ
CN101796071A (zh) * 2007-08-13 2010-08-04 诺沃-诺迪斯克有限公司 快速作用的胰岛素类似物
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
CN101784562B (zh) 2007-08-15 2016-07-13 诺沃-诺迪斯克有限公司 具有酰基和亚烷基二醇部分的胰岛素类似物
JP5547083B2 (ja) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
PT2254906T (pt) 2008-03-18 2017-01-03 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
WO2009129250A2 (fr) * 2008-04-14 2009-10-22 Case Western Reserve University Analogues de l'insuline à prendre au moment des repas de stabilité améliorée
JP2011521621A (ja) * 2008-04-22 2011-07-28 ケイス、ウエスタン、リザーブ、ユニバーシティ アイソフォーム特異的インスリン類似体
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
MX2011001408A (es) 2008-08-07 2011-05-02 Biocon Ltd Proceso para la preparacion de compuestos de insulina.
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
MX344293B (es) * 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
WO2010049488A1 (fr) 2008-10-30 2010-05-06 Novo Nordisk A/S Traitement du diabète à l’aide d’injections d’insuline avec une fréquence inférieure à une injection par jour
KR20110088575A (ko) 2008-11-21 2011-08-03 하이 포인트 파마슈티칼스, 엘엘씨 아다만틸 벤즈아미드 화합물
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
TW201105346A (en) 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
WO2011003823A1 (fr) 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Préparations d'insuline à effet retard
PT2451437T (pt) 2009-07-06 2017-01-17 Sanofi Aventis Deutschland Preparações aquosas de insulina contendo metionina
MA33466B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Composition d'insuline à longue duree d'action
CA2769340C (fr) 2009-07-31 2018-09-11 Harald Rau Promedicaments contenant un conjugue associant une sequence de liaison et de l'insuline
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
KR101772372B1 (ko) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
US8637096B2 (en) 2009-12-04 2014-01-28 Curtis C. Stojan Compositions and method for enhancing insulin activity
CA2783763A1 (fr) 2009-12-11 2011-06-16 Case Western Reserve University Analogues de l'insuline comprenant des acides amines chlores
EP2460527A1 (fr) 2010-01-21 2012-06-06 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
UY33326A (es) 2010-04-14 2011-12-01 Sanofi Aventis Conjugados de insulina-sirna
EP2569002B1 (fr) * 2010-05-10 2016-10-26 Novo Nordisk A/S Procédé de préparation de complexes d'insuline et de zinc
WO2011159895A2 (fr) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Agonistes de l'insuline à une seule chaîne très actifs au niveau du récepteur à l'insuline
RU2598273C2 (ru) * 2010-06-23 2016-09-20 Ново Нордиск А/С Производные инсулина, содержащие дополнительные дисульфидные связи
AU2011291943B2 (en) 2010-08-17 2015-01-22 Ambrx, Inc. Modified relaxin polypeptides and their uses
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
AU2011322495A1 (en) 2010-10-27 2013-04-11 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
EP2651432A1 (fr) 2010-12-14 2013-10-23 Novo Nordisk A/S Insuline à action rapide en combinaison avec une insuline à longue durée d'action
US9447163B2 (en) * 2011-02-01 2016-09-20 Novo Nordisk A/S Purification of insulin
EP2670368A4 (fr) 2011-02-03 2015-04-15 Pharmedica Ltd Nouveaux films à dissolution orale pour administration d'insuline, pour traitement du diabète
WO2012115638A1 (fr) 2011-02-23 2012-08-30 Elona Biotechnologies Compositions de pro-insuline glargine et procédés de production d'analogues de l'insuline glargine à partir de celles-ci
WO2012115637A1 (fr) * 2011-02-23 2012-08-30 Elona Biotechnologies Compositions de pro-insuline aspart et procédés de production d'analogues de l'insuline aspart
JP2014509603A (ja) 2011-03-15 2014-04-21 ノヴォ ノルディスク アー／エス システイン置換を含むヒトインスリン類似体およびヒトインスリン誘導体
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
EP2548570A1 (fr) 2011-07-19 2013-01-23 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
MX2014006698A (es) * 2011-12-15 2014-07-09 Shanghai Hengrui Pharm Co Ltd Analogo de insulina humana y derivado acilado del mismo.
WO2013096386A1 (fr) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Analogues d'insuline à base de ctp pour le traitement du diabète
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
BR112014026442A8 (pt) 2012-05-01 2018-01-16 Novo Nordisk As combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica.
WO2013173923A1 (fr) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations de kallikréine 1 de tissu humain pour l'administration parentérale et procédés associés
HUE032613T2 (en) 2012-06-04 2017-10-30 Diamedica Therapeutics Inc Human tissue kallikrein 1 is glycosylated isoforms
CN104981251B (zh) 2012-09-26 2018-03-20 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
JP6322642B2 (ja) 2012-11-13 2018-05-09 アドシア 置換されたアニオン性化合物を含有する速効型インスリン製剤
WO2014088836A1 (fr) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. Insuline et analogues d'insuline à base de peptide à partie terminale carboxy (ptc) o-glycosylée
WO2014093696A2 (fr) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Dérivés d'insuline pour le traitement du diabète
NZ707160A (en) 2012-12-19 2016-08-26 Wockhardt Ltd A stable aqueous composition comprising human insulin or an analogue or derivative thereof
CA2889162A1 (fr) 2012-12-26 2014-07-03 Wockhardt Limited Composition pharmaceutique
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
BR112015023071A2 (pt) 2013-03-14 2017-07-18 Univ Indiana Res & Tech Corp conjugados de insulina-incretina
EP2991672A1 (fr) 2013-04-30 2016-03-09 Novo Nordisk A/S Schéma d'administration d'un nouveau type
JP2016531847A (ja) 2013-09-30 2016-10-13 ウォックハート リミテッド 医薬組成物
KR20160065126A (ko) 2013-10-07 2016-06-08 노보 노르디스크 에이/에스 인슐린 유사체의 신규한 유도체
CA2932875A1 (fr) 2014-01-09 2015-07-16 Sanofi Formulations pharmaceutiques stabilisees sans glycerol d'analogues de l'insuline et/ou de derives de l'insuline
MX2016008977A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de insulina aspart estabilizadas.
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
WO2015196174A1 (fr) 2014-06-20 2015-12-23 Greene Howard E Dispositifs et procédés d'administration de perfusion
WO2016001862A1 (fr) 2014-07-04 2016-01-07 Wockhardt Limited Formulations à libération prolongée d'insulines
JP6657230B2 (ja) 2014-09-24 2020-03-04 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
KR102569743B1 (ko) 2014-10-06 2023-08-23 케이스 웨스턴 리저브 유니버시티 이상 단일 사슬 인슐린 유사체
WO2016081670A2 (fr) 2014-11-21 2016-05-26 Merck Sharp & Dohme Corp. Agonistes partiels du récepteur de l'insuline
TN2017000235A1 (en) 2014-12-12 2018-10-19 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
CN105884879A (zh) * 2015-01-26 2016-08-24 漳州博欣生物技术有限公司 一种胰岛素类似物的化学合成方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JP2018531900A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
EP3442997A2 (fr) 2016-04-15 2019-02-20 Indiana University Research & Technology Corporation Optimisation peptidique à fgf21 c-terminal
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3922260A3 (fr) 2016-05-24 2022-06-15 Merck Sharp & Dohme Corp. Agonistes partiels du récepteur de l'insuline et analogues du glp-1
EP3463413A4 (fr) 2016-05-25 2020-03-04 Merck Sharp & Dohme Corp. Agonistes partiels du récepteur de l'insuline
EP3495384A4 (fr) * 2016-08-02 2020-02-26 Jiangsu Hengrui Medicine Co., Ltd. Dérivé acylé de l'insuline humaine ou son analogue
CA3034971A1 (fr) 2016-09-29 2018-04-05 Arecor Limited Formulation d'insuline pharmaceutique
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
CA3054962A1 (fr) 2017-03-09 2018-09-13 Rick PAULS Formes posologiques de kallicreine tissulaire 1
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
MX2019014195A (es) 2017-06-01 2020-01-27 Lilly Co Eli Composiciones de insulina de rapida accion.
JP2020531451A (ja) 2017-08-17 2020-11-05 ノヴォ ノルディスク アー／エス 新規のアシル化インスリン類似体およびそれらの使用
CN111989088A (zh) 2018-04-04 2020-11-24 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
WO2019193349A1 (fr) 2018-04-04 2019-10-10 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
IL277720B2 (en) 2018-04-04 2024-03-01 Arecor Ltd A medical infusion pump system for administration of an insulin compound
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN112584853B (zh) * 2018-09-12 2021-12-10 美药星（南京）制药有限公司 一种新型门冬胰岛素原的结构和制备门冬胰岛素的方法
KR20200082618A (ko) 2018-12-31 2020-07-08 주식회사 폴루스 인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
AR120717A1 (es) * 2019-12-11 2022-03-09 Novo Nordisk As Análogos de insulina y usos de los mismos
BR112022013042A2 (pt) 2019-12-30 2022-10-18 Gan & Lee Pharmaceuticals Co Ltd Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade
JP2023510219A (ja) 2019-12-30 2023-03-13 ガン アンド リー ファーマスゥーティカルズ カンパニー リミテッド インスリン誘導体
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2252157C3 (de) * 1972-10-25 1976-03-18 Hoechst Ag Zwischenprodukte zur herstellung von insulin, insulin-analogen und -derivaten und verfahren zur herstellung von insulin, insulin analogen und derivaten
US4652525A (en) * 1978-04-19 1987-03-24 The Regents Of The University Of California Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4411994A (en) * 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4565785A (en) * 1978-06-08 1986-01-21 The President And Fellows Of Harvard College Recombinant DNA molecule
JPS55138391A (en) * 1979-04-13 1980-10-29 Shionogi & Co Ltd New synthetic method of peptide derivative
IE50892B1 (en) * 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
US4340674A (en) * 1980-05-05 1982-07-20 The Upjohn Company Cointegrate plasmids and their construction from plasmids of Escherichia and Streptomyces
US4351901A (en) * 1980-03-24 1982-09-28 Cetus Corporation Method for single nucleotide alteration
DK319780A (da) * 1980-07-24 1982-01-25 Forenede Bryggerier As Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
ZA824218B (en) * 1981-06-29 1983-04-27 Cetus Corp Plasmid for producing human insulin
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK129385A (da) * 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs

Also Published As

Publication number Publication date
IE66138B1 (en) 1995-12-13
CS275613B6 (en) 1992-03-18
ATE113061T1 (de) 1994-11-15
PT83278A (en) 1986-09-01
FI863512A0 (fi) 1986-08-29
NZ217406A (en) 1989-05-29
KR870002165A (ko) 1987-03-30
NO177009C (no) 1995-07-05
KR940000756B1 (ko) 1994-01-29
AU6206686A (en) 1987-03-05
EP0214826A3 (en) 1987-06-03
YU46857B (sh) 1994-06-24
DD268976A5 (de) 1989-06-14
PH25772A (en) 1991-10-18
JPS6253999A (ja) 1987-03-09
HUT42526A (en) 1987-07-28
AU593274B2 (en) 1990-02-08
FI863512A (fi) 1987-03-01
PT83278B (pt) 1989-03-30
AR241801A1 (es) 1992-12-30
CS8606310A2 (en) 1990-09-12
CA1306212C (fr) 1992-08-11
NO863474D0 (no) 1986-08-29
NL990042I2 (nl) 2000-03-01
EP0214826A2 (fr) 1987-03-18
FI102182B1 (fi) 1998-10-30
DE10075008I2 (de) 2004-10-21
YU46023B (sh) 1992-12-21
DE10075008I1 (de) 2000-05-18
GR862233B (en) 1986-12-31
NL990042I1 (nl) 2000-02-01
DE3650101T2 (de) 1995-02-23
NO177009B (no) 1995-03-27
CN1029977C (zh) 1995-10-11
JP2662390B2 (ja) 1997-10-08
HU206518B (en) 1992-11-30
NO2000005I1 (no) 2000-07-21
US5618913A (en) 1997-04-08
FI102182B (fi) 1998-10-30
NO863474L (no) 1987-03-02
YU4188A (en) 1990-06-30
EP0214826B1 (fr) 1994-10-19
CN86106574A (zh) 1988-08-03
YU148486A (en) 1991-04-30
DE3650101D1 (de) 1994-11-24
IE862317L (en) 1987-02-28
ES2001624A6 (es) 1988-06-01
IL79887A (en) 1991-11-21
IL79887A0 (en) 1986-11-30

Similar Documents

Publication Publication Date Title
LU90484I2 (fr) Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables
LU88576I2 (fr) RISPERIDONE et ses sels pharmaceutiquement acceptables (Risperdal R)
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU90069I2 (fr) Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
LU91147I2 (fr) Pemetrexed et ses sels pharmaceutiquement acceptables.
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU90769I2 (fr) Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda)
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
NO2001009I1 (no) Kvetiapin og farmasøytisk akseptable salter derav
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU90219I2 (fr) Tolcapone et ses dérivés pharmaceutiquement acceptables (TASMAR)
FR2631232B1 (fr) Adsorbats medicamenteux
LU88797I2 (fr) Raltitrexed et ses sels esters et hydrates pharmaceutiquement acceptables
LU91072I2 (fr) Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA
LU90866I2 (fr) Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine
KR910700249A (ko) 신규 치료학적 활성 화합물 및 그의 제조 방법
DK289886A (da) Substituerede 3-phenyl-4-cyanopyrrol-derivater samt deres fremstilling og anvendelse
LU88294I2 (fr) Pergolide et ses sels pharmaceutiquement acceptable
DK394586A (da) Fungicidt aktive propenoatderivater
MC2263A1 (fr) Aminobenzodiazepines et leurs sels pharmaceutiquement acceptables
DK678987D0 (da) Kumaranderivater samt fremstilling og brug deraf
DK346486A (da) Aminosalicylsyrederivater og farmaceutiske midler
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
LU88843I2 (fr) Ropivacaine et ses dérivés pharmaceutiquement acceptables (Naropine R)
LU88574I2 (fr) CEFEPIME et ses sels pharmaceutiquement acceptables (Maxipime R)